About SphingoTec
SphingoTec is a company based in Hennigsdorf (Germany) founded in 2002 by Andreas Bergmann.. SphingoTec has raised $36.14 million across 6 funding rounds from investors including NRW.Bank, European Union and HBM Healthcare Investments. SphingoTec operates in a competitive market with competitors including OpGen, CytoVale, Abionic, NOWDiagnostics and Proteomics International, among others.
- Headquarter Hennigsdorf, Germany
- Founders Andreas Bergmann
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sphingotec Gmbh
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$36.14 M (USD)
in 6 rounds
-
Latest Funding Round
$5.46 M (USD), Series C
Aug 08, 2024
-
Investors
NRW.Bank
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of SphingoTec
SphingoTec has successfully raised a total of $36.14M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $5.46 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series C — $5.5M
-
First Round
First Round
(01 Apr 2015)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2024 | Amount | Series C - SphingoTec | Valuation | Think.Health | |
| Dec, 2019 | Amount | Series B - SphingoTec | Valuation | Brandenburg Capital |
|
| Oct, 2018 | Amount | Series A - SphingoTec | Valuation | HBM Healthcare Investments , Wellington Partners Venture Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in SphingoTec
SphingoTec has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include NRW.Bank, European Union and HBM Healthcare Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech & life sciences focused VC firm investing in geographies such as Europe
|
Founded Year | Domain | Location | |
|
Investments are directed by Brandenburg Capital toward multiple sectors.
|
Founded Year | Domain | Location | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SphingoTec
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - SphingoTec
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sphingotec Comparisons
Competitors of SphingoTec
SphingoTec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OpGen, CytoVale, Abionic, NOWDiagnostics and Proteomics International, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| domain | founded_year | HQ Location |
Microfluidic-based biomarkers for the early detection of sepsis
|
|
| domain | founded_year | HQ Location |
Point-of-care diagnostic tools for allergy profiles are provided.
|
|
| domain | founded_year | HQ Location |
Develops rapid assay medical tests that use a single drop of blood to test for a variety of common conditions, illnesses and diseases
|
|
| domain | founded_year | HQ Location |
Medical technology company at the forefront of predictive diagnostics and bio-analytical services
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sphingotec
Frequently Asked Questions about SphingoTec
When was SphingoTec founded?
SphingoTec was founded in 2002 and raised its 1st funding round 13 years after it was founded.
Where is SphingoTec located?
SphingoTec is headquartered in Hennigsdorf, Germany. It is registered at Hennigsdorf, Brandenburg, Germany.
Who is the current CEO of SphingoTec?
Jorg Menten is the current CEO of SphingoTec.
Is SphingoTec a funded company?
SphingoTec is a funded company, having raised a total of $36.14M across 6 funding rounds to date. The company's 1st funding round was a Series A of $23.04M, raised on Apr 01, 2015.
What does SphingoTec do?
Developer of biomarker-based diagnostic solutions for cancer, cardiovascular, and other diseases. The company is involved in the development of biomarker-based in-vitro diagnostic solutions for the treatment of critical medical conditions, such as sepsis, acute heart failure, circulatory failure, and acute kidney injury. It develops a PenKid platform that measures the levels of renal hormone enkephalin and uses it to predict creatinine levels in the near future. Bio-ADM measures levels of Adrenomedullin as a biomarker for circulatory shock and vasopressor demand. It has also developed a pro-NT biomarker that measures the levels of proneurotensin to predict the risk of obesity, cardiovascular disease, and breast cancer. It provides a vr-hGH platform that measures levels of human growth hormone to predict cardiovascular risk in men.
Who are the top competitors of SphingoTec?
SphingoTec's top competitors include CytoVale, Abionic and Avails Medical.
Who are SphingoTec's investors?
SphingoTec has 8 investors. Key investors include NRW.Bank, European Union, HBM Healthcare Investments, Think.Health, and Brandenburg Capital.